A phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) in patients with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Starpharma
- 05 Feb 2018 Status changed from recruiting to completed.
- 20 Mar 2014 Status changed from not yet recruiting to recruiting, as per Australian New Zealand Clinical Trials Registry record.
- 17 Feb 2014 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12614000171617).